Home › Funds › BlueCrest Capital Management Ltd › TVTX
BlueCrest Capital Management Ltd position in TVTX
TRAVERE THERAPEUTICS INC · Health Care
BlueCrest Capital Management Ltd reported holding 5,000,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.9M, representing 0.52% of its reported portfolio and ranking #48 among its reported holdings. BlueCrest Capital Management Ltd has disclosed TVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How BlueCrest Capital Management Ltd's TVTX position evolved
BlueCrest Capital Management Ltd first disclosed a stake in TVTX in Q2 2026 at 6,000,000 shares (US$7.1M). Across 2 filings, BlueCrest Capital Management Ltd increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,000,000 shares valued at US$5.9M — a reduction of -1,000,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 6.00M | $7.08M | New |
| Q3 2026 | 5.00M | $5.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TVTX and 13F data
TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TVTX
- PERCEPTIVE ADVISORS LLC 3.75M sh · $213.18M · Q2 2026
- Rock Springs Capital Management LP 2.18M sh · $123.79M · Q2 2026
- Kynam Capital Management, LP 2.00M sh · $113.62M · Q2 2026
- Stephens Investment Management Group LLC 1.88M sh · $110.50M · Q3 2026
- EMERALD ADVISERS, LLC 1.56M sh · $92.06M · Q3 2026
- Context Capital Management, LLC 62.70M sh · $73.14M · Q3 2026
- MPM BioImpact LLC 1.12M sh · $63.78M · Q2 2026
- EMERALD MUTUAL FUND ADVISERS TRUST 984.85K sh · $57.99M · Q3 2026
- Jones Hill Capital LP 959.63K sh · $56.50M · Q3 2026
- Eversept Partners, LP 798.97K sh · $45.39M · Q2 2026
- Polar Asset Management Partners Inc. 30.50M sh · $35.91M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 28.00M sh · $32.96M · Q2 2026
More on BlueCrest Capital Management Ltd
FAQ
How long has BlueCrest Capital Management Ltd held TVTX?
BlueCrest Capital Management Ltd has disclosed TVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is BlueCrest Capital Management Ltd's current position in TVTX?
As of Q3 2026, BlueCrest Capital Management Ltd holds 5.00M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $5.94M, representing 0.52% of its reported portfolio and ranking #48.
Has BlueCrest Capital Management Ltd been buying or selling TVTX?
In the latest 13F filing (Q3 2026), BlueCrest Capital Management Ltd reduced its position in TVTX.
Which other funds hold TVTX?
Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.